Register now After registration you will be able to apply for this opportunity online.
This opportunity is not published. No applications will be accepted.
The role of BRAFV600E in pediatric gliomas
Among pediatric neoplasms, central nervous system (CNS) tumors represent the leading cause of mortality and morbidity in pediatric and young adult patients. BRAFV600E is an oncogenic mutation and targetable alteration in gliomas, the most common brain tumors across ages. Blocking the Ras/BRAF/MAPK pathway is a promising strategy in BRAFV600E-positive tumours. However, treatment failure often ensues due to acquired resistance to targeted inhibitors.
In our laboratory we have identified key pathways driving resistance to BRAFV600E inhibitors. Using a multi-omic approach (transcriptomics and proteomics), a master student will focus on exploring and targeting these resistance mechanisms, in order to optimize treatment strategies.
Keywords: Cancer biology, pediatric brain tumors, translational research, drug resistance
The candidate will have the opportunity to learn and use different molecular and cellular biology techniques (protein and nucleic acid assays, cell culture, drug screening, advanced microscopy, single cell RNA sequencing).
The candidate will have the opportunity to learn and use different molecular and cellular biology techniques (protein and nucleic acid assays, cell culture, drug screening, advanced microscopy, single cell RNA sequencing).
To decipher the molecular causes of treatment failure and optimize therapies for BRAFV600E-driven gliomas
To decipher the molecular causes of treatment failure and optimize therapies for BRAFV600E-driven gliomas
Prof. Ana Guerreiro Stücklin, MD PhD
Translational Brain Tumor Research, Kinderspital Zürich
ana.stuecklin@kispi.uzh.ch
anasofia.guerreirostuecklin@uzh.ch
Prof. Ana Guerreiro Stücklin, MD PhD Translational Brain Tumor Research, Kinderspital Zürich ana.stuecklin@kispi.uzh.ch anasofia.guerreirostuecklin@uzh.ch